Lixiana (Edoxaban)
Direct oral anticoagulant (DOAC) for stroke prevention in atrial fibrillation and treatment of venous thromboembolism
Lixiana (edoxaban) is a direct oral anticoagulant (DOAC) that belongs to the class of factor Xa inhibitors. It is prescribed to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation, and to treat and prevent recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). Taken once daily, Lixiana offers a predictable anticoagulant effect without the need for routine blood monitoring. This guide covers uses, dosage, side effects, drug interactions, and essential safety information based on international clinical guidelines.
Quick Facts
Key Takeaways
- Lixiana (edoxaban) is a once-daily direct oral anticoagulant that prevents blood clots by inhibiting factor Xa in the coagulation cascade.
- It is approved for stroke prevention in non-valvular atrial fibrillation and for treating deep vein thrombosis and pulmonary embolism in adults.
- The standard dose is 60 mg once daily, reduced to 30 mg in patients with impaired renal function, low body weight (60 kg or less), or those taking certain P-glycoprotein inhibitors.
- Lixiana can cause serious bleeding—seek immediate medical attention for any unusual or uncontrolled bleeding.
- Do not stop taking Lixiana without consulting your doctor, as abrupt discontinuation significantly increases the risk of thromboembolic events including stroke.
What Is Lixiana and What Is It Used For?
Quick answer: Lixiana contains edoxaban, a direct oral anticoagulant that prevents blood clots by blocking factor Xa. It is used to prevent stroke in atrial fibrillation and to treat venous thromboembolism (DVT and PE).
Lixiana is the brand name for edoxaban tosilate, a prescription anticoagulant medication manufactured by Daiichi Sankyo. It belongs to a class of drugs known as direct oral anticoagulants (DOACs), sometimes also referred to as novel oral anticoagulants (NOACs). Unlike older anticoagulants such as warfarin, edoxaban works by directly and selectively inhibiting factor Xa, a key enzyme in the blood coagulation cascade responsible for converting prothrombin to thrombin.
By blocking factor Xa activity, edoxaban effectively reduces thrombin generation, which in turn decreases the formation of fibrin-based blood clots. This targeted mechanism of action provides a predictable anticoagulant effect with a well-characterized dose-response relationship, eliminating the need for routine coagulation monitoring (INR testing) that is required with vitamin K antagonists like warfarin.
Approved Indications
Lixiana is approved by the European Medicines Agency (EMA) and other regulatory authorities worldwide for use in adults for the following indications:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, or prior stroke or transient ischaemic attack (TIA).
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of recurrent DVT and PE in adults, following initial treatment with a parenteral anticoagulant for at least 5 days.
The efficacy and safety of edoxaban were established in two landmark phase III clinical trials. The ENGAGE AF-TIMI 48 trial, involving over 21,000 patients with atrial fibrillation, demonstrated that edoxaban 60 mg once daily was non-inferior to warfarin for the prevention of stroke and systemic embolism while causing significantly less major bleeding. The Hokusai-VTE trial, with over 8,000 patients, showed that edoxaban was non-inferior to warfarin for the treatment of venous thromboembolism with a significantly lower rate of clinically relevant bleeding.
It is important to note that Lixiana is not suitable for patients with mechanical heart valves or moderate-to-severe mitral stenosis. These patients should continue to use vitamin K antagonists as their anticoagulant therapy.
What Should You Know Before Taking Lixiana?
Quick answer: Before starting Lixiana, inform your doctor about all medical conditions and medications. It is contraindicated in active bleeding, severe liver disease, pregnancy, breastfeeding, and in patients with mechanical heart valves.
Before your doctor prescribes Lixiana, a thorough assessment of your medical history and current medications is essential. Several conditions and circumstances can affect whether edoxaban is safe and appropriate for you, or whether dose adjustments are needed. Understanding these factors helps ensure the safest and most effective use of this anticoagulant.
Contraindications
You must not take Lixiana if any of the following apply to you:
- Allergy to edoxaban or any other ingredient in the tablet (see the Composition section for a complete list of excipients).
- Active clinically significant bleeding, including gastrointestinal haemorrhage, intracranial bleeding, or any other site of active haemorrhage.
- A disease or condition that carries a high risk of major uncontrolled bleeding, such as active peptic ulcer disease, recent brain or spinal injury, recent brain or ophthalmic surgery, recent intracranial haemorrhage, known oesophageal varices, arteriovenous malformations, or vascular aneurysms.
- Concomitant treatment with another anticoagulant (e.g., warfarin, dabigatran, rivaroxaban, apixaban, or unfractionated/low molecular weight heparin), except when switching between anticoagulant therapies or when heparin is used to maintain catheter patency.
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including patients with moderate or severe hepatic impairment (Child-Pugh B or C).
- Uncontrolled severe hypertension.
- Pregnancy and breastfeeding (see Pregnancy and Breastfeeding section below).
Warnings and Precautions
Talk to your doctor or pharmacist before taking Lixiana if you have any of the following conditions, as special caution or dose adjustment may be required:
- Increased risk of bleeding: This includes patients with congenital or acquired bleeding disorders, uncontrolled severe hypertension, active gastrointestinal ulcerative disease, retinal vascular disease (retinopathy), recent intracranial or intracerebral haemorrhage, intraspinal or intracerebral vascular abnormalities, recent brain, spinal, or ophthalmic surgery, or bronchiectasis with a history of pulmonary bleeding.
- End-stage renal disease or dialysis: Lixiana is not recommended for patients with creatinine clearance below 15 mL/min or those on dialysis, as clinical experience is limited.
- Severe hepatic impairment: Patients with liver disease that leads to impaired coagulation are at increased bleeding risk.
- Mechanical heart valves: Lixiana has not been studied in patients with mechanical prosthetic heart valves and should not be used in this population.
- Antiphospholipid syndrome: If you have been diagnosed with antiphospholipid syndrome (an autoimmune condition that increases clotting risk), inform your doctor, as DOACs may not provide adequate protection in this population.
Do not stop taking Lixiana without first consulting your doctor. Premature discontinuation of any oral anticoagulant, including edoxaban, significantly increases the risk of thromboembolic events such as ischaemic stroke. If Lixiana needs to be discontinued for any reason other than pathological bleeding or completion of therapy, your doctor should consider prescribing an alternative anticoagulant to maintain protection.
Surgery and Procedures
If you need to undergo surgery or an invasive procedure, it is critical that you take Lixiana exactly at the times your doctor instructs before and after the intervention. Where possible, Lixiana should be discontinued at least 24 hours before the procedure. Your doctor will determine when it is safe to restart edoxaban. In emergency situations, your medical team will decide on appropriate management regarding your anticoagulation therapy.
Children and Adolescents
Lixiana is not recommended for children or adolescents under 18 years of age. There is insufficient data on the safety and efficacy of edoxaban in the paediatric population.
Pregnancy and Breastfeeding
Lixiana must not be taken during pregnancy or while breastfeeding. Animal studies have shown reproductive toxicity, and the risk to the human foetus is not adequately established. Women of childbearing potential should use effective contraception throughout treatment with edoxaban. If you become pregnant while taking Lixiana, contact your doctor immediately to discuss alternative treatment options.
It is not known whether edoxaban or its metabolites are excreted in human breast milk. Available animal data show excretion of edoxaban in breast milk. Therefore, breastfeeding should be discontinued during treatment with Lixiana.
Driving and Operating Machinery
Lixiana has no or negligible effect on the ability to drive or operate machinery. Uncommon side effects such as dizziness may rarely affect individual patients; however, this is not expected to impair driving or machine operation in most individuals.
How Does Lixiana Interact with Other Drugs?
Quick answer: Lixiana interacts significantly with other anticoagulants, certain antifungals, heart rhythm medications, and some antibiotics. Some drugs increase bleeding risk while others can reduce edoxaban's effectiveness.
Drug interactions with Lixiana can broadly be categorised into two groups: those that increase the effect and bleeding risk of edoxaban, and those that decrease its anticoagulant effect. Understanding these interactions is essential for safe treatment. Always inform your doctor and pharmacist about all medications you are taking, including over-the-counter drugs, herbal supplements, and vitamins.
Major Interactions – Increased Bleeding Risk
The following drugs and drug classes can increase the effect of edoxaban or independently raise the risk of bleeding when used concurrently. Your doctor may need to reduce your edoxaban dose or increase monitoring:
| Drug / Class | Interaction Effect | Clinical Action |
|---|---|---|
| Other anticoagulants (warfarin, heparin, dabigatran, rivaroxaban, apixaban) | Additive anticoagulant effect; markedly increased bleeding risk | Contraindicated – do not use concurrently (except when switching therapy) |
| Antiplatelet agents (aspirin, clopidogrel) | Increased risk of bleeding due to additive effects on haemostasis | Use with caution; clinical monitoring recommended |
| NSAIDs (naproxen, ibuprofen) | Increased risk of gastrointestinal and other bleeding | Avoid long-term concomitant use; short-term use with caution |
| SSRIs / SNRIs (sertraline, venlafaxine) | SSRIs and SNRIs impair platelet function, increasing bleeding tendency | Monitor for signs of bleeding |
| P-gp inhibitors (ciclosporin, dronedarone, erythromycin, ketoconazole) | Increase edoxaban plasma levels by inhibiting P-glycoprotein-mediated efflux | Dose reduction to 30 mg once daily required |
| Clarithromycin | P-gp inhibition; may increase edoxaban exposure | Clinical monitoring; consider dose adjustment |
Interactions That Reduce Effectiveness
Certain drugs can reduce the anticoagulant effect of edoxaban by inducing P-glycoprotein or hepatic enzymes, potentially leading to inadequate anticoagulation and increased thromboembolic risk. Your doctor will determine if Lixiana remains appropriate for you:
| Drug / Class | Mechanism | Clinical Action |
|---|---|---|
| Rifampicin | Potent P-gp inducer; reduces edoxaban plasma concentrations | Avoid concomitant use if possible; increased monitoring if combined |
| Phenytoin | Enzyme and P-gp induction; may decrease edoxaban levels | Use with caution; monitor clinical response |
| Carbamazepine | Enzyme and P-gp induction; may decrease edoxaban levels | Use with caution; monitor clinical response |
| Phenobarbital | Enzyme induction; may reduce edoxaban efficacy | Use with caution; consider alternative anticoagulant |
| St. John’s Wort (Hypericum perforatum) | P-gp and CYP3A4 induction; reduces edoxaban exposure | Avoid concomitant use |
Important: This is not a complete list of all possible drug interactions. Always tell your doctor about all medicines you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements, before starting or stopping any medication.
What Is the Correct Dosage of Lixiana?
Quick answer: The standard adult dose of Lixiana is 60 mg once daily. The dose is reduced to 30 mg once daily for patients with impaired renal function, low body weight (≤60 kg), or those taking certain P-gp inhibitors.
Always take Lixiana exactly as your doctor has instructed. The correct dose depends on your specific clinical situation, renal function, body weight, and any concomitant medications. Lixiana is taken orally, once daily, with or without food. The tablet should be swallowed with water. If you have difficulty swallowing the tablet whole, it can be crushed and mixed with water or applesauce immediately before taking it. A crushed tablet may also be administered via a nasogastric or gastric feeding tube if necessary.
Adults
| Patient Group | Recommended Dose | Notes |
|---|---|---|
| Standard dose | 60 mg once daily | For both AF stroke prevention and VTE treatment/prevention |
| Impaired renal function (CrCl 15–50 mL/min) | 30 mg once daily | Dose reduction required due to increased edoxaban exposure |
| Low body weight (≤60 kg) | 30 mg once daily | Lower body weight associated with higher drug concentrations |
| Concomitant P-gp inhibitors (ciclosporin, dronedarone, erythromycin, ketoconazole) | 30 mg once daily | P-gp inhibitors increase edoxaban plasma levels |
Children and Adolescents
Lixiana is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of edoxaban have not been established in this population. Paediatric anticoagulation should be managed according to specific paediatric guidelines under specialist supervision.
Elderly Patients
No dose adjustment based on age alone is required for elderly patients. However, elderly individuals frequently have reduced renal function and lower body weight, both of which may require dose reduction to 30 mg once daily. The ENGAGE AF-TIMI 48 trial included substantial numbers of patients aged 75 and above, demonstrating that edoxaban provides effective stroke prevention with a favourable bleeding profile compared to warfarin in this age group. Regular monitoring of renal function is recommended in elderly patients, as age-related decline in kidney function may necessitate dose adjustments over time.
Switching Between Anticoagulants
Switching between different anticoagulants requires careful management to ensure continuous anticoagulation without excessive bleeding risk:
Switching from a Vitamin K Antagonist (e.g., Warfarin) to Lixiana
Stop the vitamin K antagonist and start Lixiana when the International Normalised Ratio (INR) falls to 2.5 or below. Your doctor will need to check blood tests and advise you on the exact timing.
Switching from Another DOAC to Lixiana
Stop the previous DOAC (dabigatran, rivaroxaban, or apixaban) and start Lixiana at the time of the next scheduled dose of the previous anticoagulant.
Switching from Parenteral Anticoagulants (e.g., Heparin) to Lixiana
Stop the parenteral anticoagulant and start Lixiana at the time of the next scheduled dose. For VTE treatment, edoxaban should be initiated following at least 5 days of initial parenteral anticoagulant therapy.
Switching from Lixiana to a Vitamin K Antagonist
For patients on 60 mg: reduce to 30 mg once daily and take alongside the vitamin K antagonist. For patients on 30 mg: reduce to 15 mg once daily and take alongside the vitamin K antagonist. Your doctor will check blood tests (INR) and tell you when to stop Lixiana. The 15 mg dose is only used during this transition period.
Missed Dose
If you miss a dose of Lixiana, take it as soon as you remember on the same day, then continue with your normal once-daily dose the following day. Do not take a double dose on the same day to make up for a missed dose. Missing doses can increase your risk of blood clots, so try to take Lixiana at the same time each day to help you remember.
Overdose
If you take more Lixiana than prescribed, contact your doctor or go to the nearest emergency department immediately. An overdose of edoxaban increases the risk of bleeding. There is no specific reversal agent widely available for edoxaban, although andexanet alfa has been approved in some regions for reversing the effects of factor Xa inhibitors in life-threatening or uncontrolled bleeding situations. Treatment of overdose is primarily supportive, with management focusing on bleeding control, haemodynamic support, and monitoring of coagulation parameters.
Never stop taking Lixiana without first speaking to your doctor. Stopping anticoagulation therapy abruptly can lead to serious thromboembolic complications, including stroke. Your doctor will advise on the safest way to transition to another therapy or discontinue treatment if needed.
What Are the Side Effects of Lixiana?
Quick answer: The most common side effects of Lixiana are bleeding (from various sites including skin, nose, gastrointestinal tract, and urinary tract), anaemia, rash, headache, dizziness, and nausea. Serious bleeding can be life-threatening.
Like all anticoagulant medicines, Lixiana can cause side effects, although not everyone experiences them. The most clinically significant risk is bleeding, which can occur at any site in the body and may be potentially life-threatening. The bleeding risk is inherent to the drug's mechanism of action as an anticoagulant.
Contact your doctor or go to the emergency department immediately if you experience: bleeding that does not stop on its own, unusual weakness or fatigue, paleness, dizziness, severe headache, unexplained swelling, vomiting blood or material resembling coffee grounds, dark or tarry stools, or blood in the urine. These may indicate serious internal bleeding requiring urgent treatment.
Common
- Bleeding from the skin or under the skin (bruising, ecchymosis)
- Nosebleeds (epistaxis)
- Gastrointestinal bleeding (stomach, intestinal)
- Bleeding from the mouth and/or throat
- Vaginal bleeding
- Blood in the urine (haematuria)
- Bleeding after injury or puncture
- Anaemia (low red blood cell count)
- Abdominal pain
- Abnormal liver function tests
- Rash
- Itching (pruritus)
- Nausea
- Headache
- Dizziness
Uncommon
- Bleeding in the eyes
- Bleeding from a surgical wound
- Coughing up blood (haemoptysis)
- Bleeding in the brain (intracranial haemorrhage)
- Other types of bleeding at various sites
- Low platelet count (thrombocytopenia)
- Allergic reaction
- Urticaria (hives)
Rare
- Bleeding in the muscles
- Bleeding in the joints (haemarthrosis)
- Intra-abdominal bleeding
- Pericardial bleeding (bleeding around the heart)
- Intracranial haemorrhage (subdural or subarachnoid)
- Post-procedural haemorrhage
- Severe allergic reaction (anaphylactic shock)
- Allergic oedema (swelling of any body part)
Frequency Not Known
- Anticoagulant-related nephropathy – bleeding in the kidneys, sometimes with blood in the urine, potentially leading to impaired renal function
Reporting Side Effects
It is important to report suspected side effects after a medicine has been authorised. This allows ongoing monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national pharmacovigilance authority. In the EU, reports can be submitted through the national reporting systems listed on the European Medicines Agency website. In the US, adverse events should be reported to the FDA MedWatch programme.
How Should You Store Lixiana?
Quick answer: Store Lixiana at room temperature, out of reach of children, and do not use after the expiry date on the packaging.
Proper storage of Lixiana helps ensure the medication remains effective and safe throughout its shelf life. Follow these guidelines:
- Keep out of sight and reach of children. Store the medication in a secure location where children cannot access it.
- No special storage conditions are required. Lixiana film-coated tablets can be stored at room temperature. There is no need for refrigeration or protection from specific environmental conditions.
- Check the expiry date. Do not use Lixiana after the expiry date (EXP) printed on the carton and blister pack. The expiry date refers to the last day of the stated month.
- Dispose of properly. Do not dispose of medicines through household waste or down the drain. Ask your pharmacist about proper medicine disposal methods to help protect the environment.
If you notice any changes in the appearance of your tablets (discolouration, crumbling, unusual odour), do not take them and consult your pharmacist. Always keep the tablets in their original packaging (blister pack or bottle) until ready to use.
What Does Lixiana Contain?
Quick answer: Each Lixiana tablet contains edoxaban (as tosilate) as the active ingredient, along with inactive excipients including mannitol, pregelatinised starch, and various film-coating components. Tablets are available in 15 mg, 30 mg, and 60 mg strengths.
Active Ingredient
The active substance in all Lixiana tablets is edoxaban (in the form of edoxaban tosilate). Edoxaban tosilate is a tosilate salt form that provides optimal oral bioavailability and stability.
Tablet Strengths and Appearance
| Strength | Colour | Shape & Size | Imprint |
|---|---|---|---|
| 15 mg | Orange | Round, 6.7 mm diameter | DSC L15 |
| 30 mg | Pink | Round, 8.5 mm diameter | DSC L30 |
| 60 mg | Yellow | Round, 10.5 mm diameter | DSC L60 |
Inactive Ingredients (Excipients)
In addition to the active ingredient, each tablet contains the following excipients:
Tablet core: Mannitol (E421), pregelatinised starch, crospovidone (E1202), hydroxypropylcellulose (E463), magnesium stearate (E470b).
Film coating: Hypromellose (E464), macrogol 8000, titanium dioxide (E171), talc (E553b), carnauba wax. The 15 mg tablet coating also contains red iron oxide (E172) and yellow iron oxide (E172). The 30 mg tablet coating also contains red iron oxide (E172). The 60 mg tablet coating also contains yellow iron oxide (E172).
Packaging
Lixiana is available in blister packs and unit-dose blisters in various pack sizes. The 30 mg and 60 mg tablets are available in packs of 10, 14, 28, 30, 56, 60, 84, 90, 98, or 100 film-coated tablets, or in unit-dose blisters of 10, 50, or 100 tablets, and bottles of 90 tablets. The 15 mg tablets are available in packs of 10 tablets. Not all pack sizes may be available in all markets.
Marketing Authorisation Holder
Lixiana is manufactured by Daiichi Sankyo Europe GmbH, Munich, Germany. The medication is marketed globally under the brand names Lixiana (Europe and many other regions) and Savaysa (United States).
Frequently Asked Questions About Lixiana
Medical References and Sources
This article is based on current medical research, regulatory information, and international clinical guidelines. All sources are peer-reviewed or from recognised regulatory and medical bodies.
- Giugliano RP, Ruff CT, Braunwald E, et al. (2013). "Edoxaban versus Warfarin in Patients with Atrial Fibrillation." New England Journal of Medicine, 369(22), 2093–2104. https://doi.org/10.1056/NEJMoa1310907 ENGAGE AF-TIMI 48 trial – landmark phase III RCT comparing edoxaban to warfarin in 21,105 AF patients. Evidence level: 1A
- Hokusai-VTE Investigators (2013). "Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism." New England Journal of Medicine, 369(15), 1406–1415. https://doi.org/10.1056/NEJMoa1306638 Hokusai-VTE trial – phase III RCT comparing edoxaban to warfarin for VTE treatment in 8,292 patients. Evidence level: 1A
- European Medicines Agency (2024). "Lixiana (edoxaban) – Summary of Product Characteristics." EMA/EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/lixiana Official European regulatory documentation including full prescribing information. Regulatory source.
- Hindricks G, Potpara T, Dagres N, et al. (2021). "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation." European Heart Journal, 42(5), 373–498. https://doi.org/10.1093/eurheartj/ehaa612 ESC clinical practice guidelines recommending DOACs as first-line anticoagulation in eligible NVAF patients. Evidence level: 1A
- Steffel J, Collins R, Antz M, et al. (2021). "2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants." European Heart Journal, 42(25), 2523–2544. https://doi.org/10.1093/eurheartj/ehab065 EHRA practical guide for DOAC use, including edoxaban-specific recommendations for special populations. Evidence level: Expert consensus.
- National Institute for Health and Care Excellence (2020). "Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism." NICE Technology Appraisal TA354. https://www.nice.org.uk/guidance/ta354 NICE health technology assessment recommending edoxaban as an option for VTE treatment and prevention. Evidence level: Health technology assessment.
Evidence grading: This article uses the GRADE framework for evaluating medical evidence. Level 1A represents the highest quality evidence, based on systematic reviews and meta-analyses of randomised controlled trials. All recommendations are consistent with current European Society of Cardiology (ESC) guidelines and European Medicines Agency (EMA) approved prescribing information.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two independent specialist physicians before publication. Drug information is cross-referenced with official regulatory documentation (EMA, FDA).
Fact-Checking
Every medical claim is verified against peer-reviewed sources and international clinical guidelines. We use the GRADE framework to evaluate the strength of evidence.
Update Frequency
Articles are reviewed and updated at least every 12 months, or sooner when significant new evidence, guideline changes, or safety alerts are published.
Corrections Policy
If errors are identified, corrections are made promptly and transparently. Material changes are documented with updated review dates.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians, pharmacists, and researchers who oversee all published medical content. Our editorial process ensures adherence to international medical standards including ESC, EHRA, EMA, and WHO guidelines.